Splenic disorder

This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…

This study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…

This early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …

This early-stage trial tested a drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin Lymphoma that had come back or not responded to prior treatments. The main goals were to check safety and find the right dose. The study was termin…

This early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…

This phase 2 study tested umbralisib (a PI3K blocker) plus rituximab (an antibody that targets B-cells) as the first treatment for people with follicular or marginal zone lymphoma. The goal was to see how many patients had their tumors disappear completely. Only 18 people enrolle…

This phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and rituximab (Truxima), in 22 people with marginal zone lymphoma, a type of blood cancer. The goal was to see if this chemotherapy-free approach could control the disease with fewer side effects than …

This study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…

This early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…

This phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…

This phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very l…

This study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…

This phase 3 trial tested a new radioactive imaging agent called [68Ga]Ga-PentixaFor to see if it could better detect lymphoma tumors compared to the standard PET scan. The study aimed to enroll adults with marginal zone lymphoma who had not yet been treated. However, the trial w…

This study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to …